Clinical Features and Prognosis of Bone Metastases

Textbook of Bone Metastases

Volumn , Issue , 2006, Pages 63-75

  Coleman, Robert E ^a   Plunkett, T A ^b   Rubens, R D ^b  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Bone metastases; Cranial nerve palsies; Hypercalcaemia; Multiple myeloma; Prognosis of bone metastases; Prostate cancer; Radionuclide bone scans; Skeletal metastatic disease; Spinal cord compression

Indexed keywords

EID: 84889395719     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470011610.ch5     Document Type: Chapter

References (46)

1. Galasko C. The anatomy and pathways of skeletalmetastases. In Weiss L, Gilbert A (eds), Bone Metastases.GK Hall: Boston, 1981: 49-63.
2. Batson O. The role of vertebral veins in metastaticprocesses. Ann Intern Med 1942; 16: 38-45.
3. Bundred N et al. Parathyroid hormone related protein andskeletal morbidity in breast cancer. Eur J Cancer 1992; 28:690-2.
4. Coleman R, Rubens R. The clinical course of bonemetastases in breast cancer. Br J Cancer 1987; 77: 336-40.
5. Koenders P et al. Steroid hormone receptor activity ofprimary human breast cancer and pattern of firstmetastasis. Breast Cancer Res Treat 1991; 18: 27-32.
6. Fang K, Peng C. Predicting the probability of bonemetastasis through histological grading of prostatecarcinoma: a retrospective correlative analysis of 81autopsy cases with ante-mortem transurethral resectionspecimens. J Urol 1983; 57: 715-20.
7. Rivkees A, Crawford J. The relationship of gonadalactivity and chemotherapy-induced gonadal damage. JAm Med Assoc 1988; 259: 2123-5.
8. Saarto T et al. Chemical castration induced by adjuvantcyclophosphamide, methotrexate and fluorouracil chemotherapycauses rapid bone loss that is reduced byclodronate: a randomised study in premenopausal breastcancer patients. J Clin Oncol 1997; 15: 1341-7.
9. Powles T et al. The effect of tamoxifen on lumbar bonemineral density in pre- and post-menopausal women. JClin Oncol 1996; 14: 78-84.
10. Daniell H. Osteoporosis after orchiectomy for prostatecancer. J Urol 1997; 157: 439-44.
11. Edelstyn G, Gillespie P, Grebbel F. The radiologicaldemonstration of osseous metastases: experimentalobservations. Clin Radiol 1967; 18: 158-61.
12. Fogelman I, Coleman R. The bone scan and breastcancer. In Freeman L, Weisman H (eds), NuclearMedicine Annual. Raven: New York, 1988: 1-14.
13. Muindi J et al. The role of computed tomography in thedetection of bone metastases in breast cancer patients. BrJ Cancer 1983; 56: 233-6.
14. Traill Z et al. Magnetic resonance imaging versusradionuclide scintigraphy in screening for bone metastases.Clin Radiol 1999; 54: 448-51.
15. Urwin G et al. Generalised increase in bone resorption incarcinoma of the prostate. Br J Urol 1985; 57: 721-3.
16. Garnero P et al. Markers of bone turnover for themanagement of patients with bone metastases fromprostate cancer. Br J Cancer 2000; 82: 858-64.
17. Domchek S et al. Predictors of skeletal complications inpatients with metastatic breast carcinoma. Cancer 2000;89: 363-8.
18. Plunkett T, Smith P, Rubens R. Risk of complicationsfrom bone metastases in breast cancer: implications formanagement. Eur J Cancer 2000; 36: 476-82.
19. Coleman R, Smith P, Rubens R. Clinical course andprognostic factors following bone recurrence from breastcancer. Br J Cancer 1998; 77: 336-40.
20. Landis S et al. Cancer statistics. CA Cancer J Clin 1999;49: 8-29.
21. Robson M, Dawson N. How is androgen-dependentmetastatic prostate cancer best treated? Hematol OncolClin North Am 1996; 10: 727-47.
22. Eisenberger M, Crawford E, Wolf M. Prognostic factorsin stage D2 prostate cancer: important implications forfuture trials. Semin Oncol 1994; 21: 613-19.
23. Matzkin H, Perito P, Soloway M. Prognostic factors inmetastatic prostate cancer. Cancer 1993; 72(SUPPL 12):3788-92.
24. Crawford E, Eisenberger M, McLeod K. A controlledtrial of leuprolide with and without flutamide in prostaticcarcinoma. N Engl J Med 1989; 321: 419-24.
25. Soloway M, Hardeman S, Hickey D. Stratification ofpatients with metastatic prostate cancer based on extentof disease on initial bone scan. Cancer 1988; 61: 195-202.
26. Sabbatini P et al. Prognostic significance of extent ofdisease in bone in patients with androgen-independentprostate cancer. J Clin Oncol 1999; 17: 948-57.
27. International Commission on Radiological Protection.Report of the Task Force Group on the Reference Man.Pergamon Press: New York, 1975.
28. Akimoto S et al. Inability of bone turnover marker as astrong prognostic indicator in prostate cancer patientswith bone metastasis: comparison with the extent ofdisease (EOD) grade. Prostate 1999; 38: 28-34.
29. Smith M, Newland A. Treatment of myeloma. Qu J Med1999; 92: 11-14.
30. Bataille R, Boccadoro M, Klein B. C-reactive protein andb-2 microglobulin produce a simple and powerfulmyeloma staging system. Blood 1992; 80: 733-9.
31. Fonseca R et al. Prognostic value of serum markers ofbone metabolism in untreated multiple myeloma patients.Br J Haematol 2000; 109: 24-9.
32. McCloskey E et al. Natural history of skeletal disease inmultiple myelomatosis and treatment with clodronate.Bone Min 1992; 28(SUPPL 1): S27-31.
33. Mercadante S. Malignant bone pain: pathophysiologyand treatment. Pain 1997; 69: 1-18.
34. Front D et al. Bone metastases and bone pain in breastcancer. J Am Med Assoc 1979; 242: 1747-8.
35. Muggia F. Overview of cancer-related hypercalcaemia:epidemiology and etiology. Semin Oncol 1990;17(SUPPL 5): 3-9.
36. Coleman R, Fogelman I, Rubens R. Hypercalcaemia andbreast cancer: an increased humoral component inpatients with liver metastases. Eur J Surg Oncol 1988;14: 423-8.
37. Body J, Delmas P. Urinary pyridinium crosslinks asmarkers of bone resorption in tumor-associated hypercalcaemia.J Clin Endocrinol Metab 1992; 74: 471-5.
38. Grill V et al. Parathyroid hormone-related protein:elevated levels in both humoral hypercalcaemia ofmalignancy and hypercalcaemia complicating metastaticbreast cancer. J Clin Endocrinol Metab 1991; 73: 1309-15.
39. Mirels H. Metastatic disease in long bones: a proposedscoring system for diagnosing impending pathologicalfractures. Clin Orthoped Clin Res 1989; 249: 256-64.
40. Douglass H, Shukla S, Mindell E. Treatment ofpathological fractures of long bones excluding thosedue to breast cancer. J Bone Joint Surg Am 1976; 58:1055-61.
41. Hill M et al. Spinal cord compression in breast cancer: areview of 70 cases. Br J Cancer 1993; 68: 969-73.
42. Sorensen S et al. Effect of high-dose dexamethasone incarcinomatous metastatic spinal cord compression treatedwith radiotherapy. Eur J Cancer 1994; 1: 22-7.
43. Heimdal K et al. High incidence of serious side effects ofhigh-dose dexamethasone treatment in patients withepidural spinal cord compression. J Neurooncol 1992;12: 141-4.
44. Maranzano E, Latini P. Effectiveness of radiationtherapy without surgery in metastatic spinal cordcompression: final results from a prospective trial. Int JRadiat Oncol Biol Phys 1995; 32: 959-67.
45. Young R, Post E, King G. Treatment of spinal epiduralmetastases. Randomised prospective comparison oflaminectomy and radiotherapy. J Neurosurg 1980; 53:741-8.
46. Loblaw D, Laperriere N. Emergency treatment ofmalignant extradural spinal cord compression: anevidence-based guideline. J Clin Oncol 1998; 16: 1613-24.